These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Simultaneous determination of evobrutinib and its metabolite evobrutinib-diol in dog plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry.
    Author: Yang J, Yu H, Tang Q.
    Journal: Biomed Chromatogr; 2019 Sep; 33(9):e4575. PubMed ID: 31069837.
    Abstract:
    A rapid and sensitive liquid chromatography hyphenated with electrospray ionization tandem mass spectrometric method (LC-ESI-MS/MS) was developed and validated for simultaneous determination of evobrutinib and evobrutinib-diol in dog plasma. The plasma sample was processed using acetonitrile and chromatographic separation was carried out on a Waters Acquity BEH C18 column (50 × 2.1 mm, 1.7 μm). The mobile phase was composed of 0.1% formic acid and acetonitrile, with an optimized gradient elution at a flow rate of 0.4 mL/min. Detection was accomplished in selective reaction monitoring mode via electrospray ionization interface operated in positive ion mode. The precursor-to-product transitions for quantification were m/z 430.2 → 98.1 for evobrutinib, m/z 464.2 → 98.1 for evobrutinib-diol and m/z 441.2 → 138.1 for ibrutinib (internal standard). The developed assay was linear over the tested concentration ranges with correlation coefficient >0.995. The LLOQ was 0.1 ng/mL for both analytes. The inter- and intra-day precisions were <9.65% and the accuracy ranged from -3.94 to 6.37%. The extraction recovery was >85.41% and no significant matrix effect was observed. The developed assay was successfully applied to the pharmacokinetic study of evobrutinib and evobrutinib-diol in dogs after oral administration of evobrutinib at a single dose of 5 mg/kg.
    [Abstract] [Full Text] [Related] [New Search]